Results 41 to 50 of about 9,978 (177)
Beta‐Thalassemia in Spain: Results From the National Thalassemia Registry and Molecular Analysis of Patients With Transfusion‐Dependent Thalassemia
Journal of Clinical Laboratory Analysis, Volume 40, Issue 14, July 2026.This nationwide registry‐based study describes the clinical and molecular characteristics of 78 patients with transfusion‐dependent beta‐thalassemia in Spain. Comprehensive genetic analysis revealed marked molecular heterogeneity, with 24 HBB mutations identified and a predominance of β0 genotypes, alongside generally effective transfusion and iron ...Ana Villegas, Paloma Ropero, Fernando Ataulfo González, Marta Morado, María Menor, Silvia de la Iglesia, Montserrat López‐Rubio, Eduardo José Salido, Mariola Abío, María Leonor Senent, Valle Recasens, José Manuel Vagace, Cristina Fonte, Jesús María Hernández‐Rivas, José María Raya, Pablo Ríos, Valeria Luciana Peri, Keneth A. Herrera, María Concepción Tenorio, Laura Lo Riso, Juan Tena, María Angustias Molina, Miriam Vara, Isabel Rodríguez, Pilar Ricard, Miguel Gómez, Oana Popa Dusacovschi, Julia María Vidán, Jorge Groiss, Óscar Ferre, Irene Orbe, Rosa María López, Nazaret Ugalde, Manuela Inés Hidalgo, Cristina Hinojosa, Ana Isabel Rodríguez, Esther Herrera, María Josefa Murúzabal, María del Carmen Hernández, Josefa Esperanza Marco, Celina Benavente, Grupo Español de Eritropatología +41 morewiley +1 more sourceDistribution of adult T‐cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study
British Journal of Haematology, Volume 209, Issue 1, Page 107-115, July 2026.Summary
Although adult T‐cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366 ...Bryan Valcarcel, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Kenji Ishitsuka, Yasushi Takamatsu, Junji Suzumiya, Kazuo Tamura, Jule F. Vasquez, Daniel Enriquez‐Vera, Brady E. Beltran, Denisse Castro, Thanya Runciman, Henry Idrobo, Elizabeth Arrieta, Oriana Arias, Eduardo Gotuzzo, Gabriela Garrido‐Pinzás, Victor Rivera, Daniel La Rosa, Camila Peña, Lorena Fiad, Juan C. Ramos, Jose Sandoval‐Sus, Alejandro Sica, Britney N. Bell, Lucy B. Cook, Veronica Leataud, Eliana C. M. Miranda, Carlos Chiattone, Hiroo Katsuya, Luis Malpica +31 morewiley +1 more sourceEXPERIÊNCIA DO USO DA RECUPERAÇÃO INTRAOPERATÓRIA DE SANGUE EM CIRURGIAS DE ARTRODESE TORACO LOMBAR
Hematology, Transfusion and Cell TherapyA cirurgia de artrodese toraco-lombar envolve elevada perda sanguínea e necessita frequentemente de hemotransfusão. O custo e os riscos envolvidos no uso do sangue alogênico têm motivado pesquisas de métodos capazes de reduzir o sangramento operatório ...TO Rebouças, CMF Lima, JS Alves, FC Souza, MGG Jorge, JBF Oliveira, EL Silva, FJC Santos, TB Soares, LMB Carlos +9 moredoaj +1 more sourceReal‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database
Haemophilia, Volume 32, Issue 4, Page 989-1001, July/August 2026.ABSTRACT Introduction
Prophylactic factor replacement and non‐factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real‐world settings, despite availability of newer therapies, are not well documented.Víctor Jiménez Yuste, Cléa Percier, Shwetha Prashanth, Nathan Ball, Ella Morton, Giancarlo Castaman +5 morewiley +1 more sourceESTUDO COMPARATIVO ENTRE OS MÉTODOS SOROLÓGICO E MOLECULAR NA INVESTIGAÇÃO DA INFECÇÃO PELO HIV NA TRIAGEM DE DOADORES DE SANGUE DO INSTITUTO DE HEMATOLOGIA E HEMOTERAPIA DO AMAPÁ
Hematology, Transfusion and Cell TherapyIntrodução: Os testes sorológicos e moleculares que são utilizados em bancos de sangue têm o objetivo de identificar precocemente indivíduos infectados, aumentando com isso a segurança tranfusional.IGL Lopes, RF Frazão, JC Lima, AN Costa, RS Deniur, MLA Souza, JCS Batista, SS Borges, HTO Bittencourt, ES Lage +9 moredoaj +1 more sourceEfficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis
HemaSphere, Volume 10, Issue 6, June 2026.Abstract
Neurodegenerative Langerhans cell histiocytosis (ND‐LCH) is a severe and debilitating complication of LCH with no effective treatment. In this study, we assessed the efficacy of MAPK inhibitors (MAPKi) in a large cohort of children with ND‐LCH. We included pediatric patients with ND‐LCH who received MAPKi between 2013 and 2025.Francesco Pegoraro, Francois Chalard, Dmitry Evseev, Mohamed Barkaoui, Solenne Le Louet, Julian Thalhammer, Nathalie Aladjidi, Alexandra Salmon, Perrine Marec‐Berard, Stefania Gaspari, Carmela De Fusco, Irene Trambusti, Antonio Verrico, Anna Raciborska, Karel Svojgr, Zdenka Křenová, Olga Slater, Gerard Millen, Myriam Ben Arush, Dana Ashkenazi Lustig, Tatiana Von Bahr Greenwood, Caroline Hutter, Itziar Astigarraga, Mónica López‐Duarte, Lorena Valero‐Arrese, María José Ortega Acosta, Cor van den Bos, Leonie Naeije, Daniel Martin‐Munoz, Anna Perrone, Marzia Mortilla, Olivier Felician, Ahmed Idbaih, Sébastien Héritier, Vasanta Nanduri, Milen Minkov, Jan‐Inge Henter, Elena Sieni, Jean Donadieu +38 morewiley +1 more sourcePB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
HemaSphere, 2022 A. Navickas, J. González, M. M. Rivas, M. Clavijo, N. Carnelutto, M. E. Funes, M. J. Mela Osorio, R. Mariano, M. L. Rapan, M. Moirano, I. Rey, S. Cranco, J. E. Giunta, R. Ramirez, M. B. Castro, A. Enrico, A. Gimenez Conca, C. Belli +17 moredoaj +1 more sourceReal-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort
Frontiers in OncologyBackgroundIsatuximab, an anti-CD38 monoclonal antibody, is a cornerstone therapy for multiple myeloma (MM). Standard intravenous infusion requires a minimum of 75 minutes per dose, representing a significant burden on patients and day-hospital resources. Xabier Gutiérrez López De Ocáriz, Ernesto Pérez Persona, Laura Salcedo Cuesta, Eusebio Martín Chacón, Maialen Sirvent Auzmendi, Pamela Millacoy Austerrritt, Marcos Lorenzo Pérez, Elena Landete Hernández, Vicente Carrasco Baraja, Irene Sanchéz Romero, Tania Ivett Arámbula, Ianire Etxeguren Urkixo +11 moredoaj +1 more source
